New milestone for next-gen treatment by Dualyx (Flanders)

Founded by Luc Van Rompaey, a former executive at Galapagos and Argenx, Dualyx combines the expertise of Argenx with the research projects of VIB (Flanders’ strategic research center for biotechnology and life sciences) as well as three universities: UGent and KU Leuven in Flanders, and Universität Würzburg in Germany. This unique collaboration has resulted in a pioneering approach to activate regulatory T-cells, restoring balance in the immune system and reducing the exaggerated immune response that causes damage in autoimmune diseases. 

The impressive funding amount of EUR 40 million comes from a consortium of European investors led by Fountain Healthcare Partners, Forbion, and Andera Partners. This substantial investment, particularly for a company that is only three years old and still in the early stages of development, demonstrates the high level of confidence in both Dualyx’s team and technology. 

Dualyx’s innovative treatment approach addresses a significant unmet need in the field of autoimmune diseases. By selectively activating regulatory T-cells, the company aims to develop medications with fewer side effects, revolutionizing the treatment landscape for rheumatoid arthritis, psoriasis and various other autoimmune conditions.

While Dualyx’s research is still in the laboratory phase, the company is preparing to initiate the first clinical trials on patients in 2024. Commercialization of its pioneering treatments is not expected until at least 2030. However, the early success and promising potential of Dualyx’s approach already attracted a lot of attention and investor support.

This success story further highlights the innovative capabilities of companies and organizations in Flanders’ life sciences & health industry. Dualyx joins the ranks of other successful spin-offs, including Agomab, which raised USD 140 million within 5 years of its inception. The strong foundation and collaboration between Flanders-based companies and research institutions foster an environment of scientific excellence and entrepreneurial spirit, driving breakthrough discoveries in the biotech field. 

Dualyx’s remarkable progress and recently secured funding are also a testament to the strides being made in the treatment of autoimmune diseases. As Dualyx continues its journey toward commercialization, the hope is that its groundbreaking approach will provide patients with more effective and safer treatment options, ultimately improving the lives of millions affected by autoimmune diseases worldwide.